Compare Heron Therapeutics Inc (HRTX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Jumia Technologies AG - ADR — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Jumia Technologies AG - ADR trades at $6.32 (market cap $719.58M). The key difference: Jumia Technologies AG - ADR is far larger — about 11.7× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | JMIA | |
|---|---|---|
Market Cap | $61.47M | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $14.60 |
52-Week Low | $0.32 | $5.69 |
Enterprise Value | $168.21M | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
JMIA trades at $6.245, up 4.08% on the day, amid a bearish technical signal and mixed fundamentals. The company reported revenue of $188.93M for 2025 with a gross profit margin of 54.75%, but net losses persist, and recent earnings have missed expectations. Analyst consensus is strongly bullish with 71.43% buy ratings, while technical indicators show selling pressure.
The outlook hinges on JMIA's path to profitability, targeting Q4 2026 breakeven and 2027 profitability. Risks include high cash burn and competitive pressures, but gross profit growth and strategic partnerships offer potential upside for patient investors focused on the African e-commerce market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
